Empowered Funds LLC Has $988,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Empowered Funds LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 280.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,704 shares of the medical equipment provider's stock after purchasing an additional 10,101 shares during the quarter. Empowered Funds LLC's holdings in Hologic were worth $988,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in HOLX. Creative Planning increased its position in shares of Hologic by 16.6% during the 3rd quarter. Creative Planning now owns 25,430 shares of the medical equipment provider's stock worth $2,072,000 after purchasing an additional 3,617 shares during the last quarter. Swedbank AB increased its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Hologic by 23.9% during the 3rd quarter. Bleakley Financial Group LLC now owns 6,368 shares of the medical equipment provider's stock worth $519,000 after acquiring an additional 1,227 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Hologic by 37.0% during the 3rd quarter. Blue Trust Inc. now owns 7,118 shares of the medical equipment provider's stock worth $528,000 after acquiring an additional 1,923 shares during the last quarter. Finally, OLD National Bancorp IN acquired a new position in shares of Hologic during the 3rd quarter worth approximately $204,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent analyst reports. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. Raymond James reissued an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $85.77.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $0.15 during trading on Friday, reaching $64.47. 2,212,653 shares of the company traded hands, compared to its average volume of 2,473,213. The company's 50 day moving average is $69.91 and its two-hundred day moving average is $76.61. The firm has a market capitalization of $14.47 billion, a PE ratio of 20.34, a PEG ratio of 2.13 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $62.69 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.